Metronomic Therapy in Patients With Metastatic Melanoma
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low
Dose Vinblastine, Cyclophosphamide, and Dacarbazine.
Patients with measurable metastatic melanoma are eligible. All patients will be treated as
outlined below with combined vinblastine, cyclophosphamide, and dacarbazine. Patients will be
treated continuously, until evidence of progression of disease, or for up to two cycles
following disappearance of all disease. A cycle will be defined as three weeks of continuous
therapy with a one week rest.